CA2838155C - Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 - Google Patents

Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 Download PDF

Info

Publication number
CA2838155C
CA2838155C CA2838155A CA2838155A CA2838155C CA 2838155 C CA2838155 C CA 2838155C CA 2838155 A CA2838155 A CA 2838155A CA 2838155 A CA2838155 A CA 2838155A CA 2838155 C CA2838155 C CA 2838155C
Authority
CA
Canada
Prior art keywords
tissue damage
protease
cell derived
stromal cell
sdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2838155A
Other languages
English (en)
French (fr)
Other versions
CA2838155A1 (en
Inventor
Anthony Sandrasagra
Weitao Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CA2838155A1 publication Critical patent/CA2838155A1/en
Application granted granted Critical
Publication of CA2838155C publication Critical patent/CA2838155C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2838155A 2011-06-07 2012-06-06 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 Active CA2838155C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494079P 2011-06-07 2011-06-07
US61/494,079 2011-06-07
PCT/US2012/041054 WO2012170495A1 (en) 2011-06-07 2012-06-06 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Publications (2)

Publication Number Publication Date
CA2838155A1 CA2838155A1 (en) 2012-12-13
CA2838155C true CA2838155C (en) 2021-10-19

Family

ID=47296407

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838155A Active CA2838155C (en) 2011-06-07 2012-06-06 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Country Status (8)

Country Link
US (1) US10662234B2 (https=)
EP (1) EP2717894B1 (https=)
JP (2) JP6145089B2 (https=)
CN (1) CN103747795A (https=)
AU (2) AU2012268078B2 (https=)
CA (1) CA2838155C (https=)
IL (1) IL229697A0 (https=)
WO (1) WO2012170495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AU2014362198A1 (en) * 2013-12-13 2016-07-07 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN107073078B (zh) 2014-09-26 2021-07-06 赫利世弥斯株式会社 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
CN114366806A (zh) * 2021-12-16 2022-04-19 天津市泌尿外科研究所 一种纳米黑磷负载sdf-1的纳米药物复合体及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
WO1993010261A1 (en) 1991-11-13 1993-05-27 Dahlbaeck Bjoern Method for the diagnosis of blood coagulation disorders
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20020107196A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6440934B1 (en) * 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
DE10027383A1 (de) 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
JP2004534723A (ja) 2000-11-09 2004-11-18 ジェネティクス インスティテュート，エルエルシー 腫瘍ワクチンとしてのＳＤＦ−１β発現腫瘍細胞
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用
US20020156023A1 (en) 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
AU2002348241A1 (en) 2001-11-24 2003-06-10 Image Analysis, Inc. Automatic detection and quantification of coronary and aortic calcium
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1503786A2 (en) 2002-05-10 2005-02-09 IPF Pharmaceuticals GmbH A method of inhibiting the emigration of cells from the intravascular compartment into tissues
US7485141B2 (en) 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
US20050065064A1 (en) 2002-08-09 2005-03-24 Elias Lolis Identification of allosteric peptide agonists of CXCR4
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP2006502142A (ja) 2002-08-23 2006-01-19 ブリストル−マイヤーズ　スクイブ　カンパニー 虚血性損傷を減少させる方法
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004094465A2 (en) 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
EP1803464A4 (en) 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
WO2006047315A2 (en) 2004-10-25 2006-05-04 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
US20060110374A1 (en) 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
EP1833504A4 (en) 2005-01-04 2009-08-12 Brigham & Womens Hospital PERMANENT DELIVERY OF SELF-ARRANGING PEPTIDE NANOFIBER USING THE PDGF
US8153592B2 (en) 2005-01-10 2012-04-10 Mayo Foundation For Medical Education And Research Modulating toll-like receptor activity
EP1879606B1 (en) 2005-04-25 2013-06-12 Massachusetts Institute of Technology Self-assembling peptides for promoting hemostasis
BRPI0617823A2 (pt) * 2005-10-31 2011-08-09 Laboratoires Serono Sa uso de sdf-1 para o tratamento e/ou prevenção de doenças neurológicas e composição farmacêutica
WO2007079460A2 (en) 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
TW200817437A (en) 2006-08-11 2008-04-16 Medarex Inc Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20080194478A1 (en) 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
JP2010523496A (ja) 2007-03-30 2010-07-15 ザ クリーブランド クリニック ファウンデーション 虚血障害の治療方法
ES2325715B1 (es) 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
US8414924B2 (en) 2007-10-10 2013-04-09 Kyoto University Preparation for treating heart disease used in cell therapy
ATE543507T1 (de) * 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
EP2100954A1 (en) 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
EP2335744A4 (en) 2008-08-26 2011-07-27 Univ Hokkaido Nat Univ Corp BONE-FILLING AGENT FOR INTRODUCING CARTILAGE REGENERATION
US9072765B2 (en) 2009-05-20 2015-07-07 Board Of Regents, The University Of Texas System Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012027170A1 (en) 2010-08-23 2012-03-01 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
JP5464276B2 (ja) * 2010-08-27 2014-04-09 富士通株式会社 並列計算機、並列計算機のジョブ情報取得プログラム、並列計算機のジョブ情報取得方法、計算装置及び計算管理装置
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AU2014362198A1 (en) 2013-12-13 2016-07-07 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Also Published As

Publication number Publication date
EP2717894A1 (en) 2014-04-16
EP2717894B1 (en) 2018-01-24
JP2017114867A (ja) 2017-06-29
AU2017213440A1 (en) 2017-08-24
US20140199304A1 (en) 2014-07-17
IL229697A0 (en) 2014-01-30
CA2838155A1 (en) 2012-12-13
CN103747795A (zh) 2014-04-23
AU2012268078A1 (en) 2013-12-19
JP2014519514A (ja) 2014-08-14
EP2717894A4 (en) 2015-02-25
AU2012268078B2 (en) 2017-06-01
WO2012170495A1 (en) 2012-12-13
US10662234B2 (en) 2020-05-26
JP6145089B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
ZA202202410B (en) Rna particles comprising polysarcosine
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
IN2012DN02645A (https=)
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
WO2018013583A3 (en) Medicinal vaginal lactobacillus cocktail
NZ603901A (en) Vectors and sequences for the treatment of diseases
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
HK1215934A1 (zh) 肽治疗剂及其使用方法
WO2016201380A8 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
NZ603386A (en) Pharmaceutical compositions and administrations thereof
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
MY162350A (en) Humanized anti-factor d antibodies and uses thereof
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
CA2838155C (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2012093258A3 (en) Irf5- related treatment and screening
WO2015195684A3 (en) Small molecule anti-scarring agents
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
JO3591B1 (ar) مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
BR112014011733A2 (pt) suspensões autoclaváveis da forma 2 de ciclosporina a
WO2016033432A9 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170405

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251223

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260330

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407